GEN Exclusives

More »
New Products

Related to High-Throughput AlphaLISA Analysis

    • Chromatographic Photo Diode Array Detector
    • PerkinElmer
    • The PDA Plus™, a member of the Flexar™ liquid chromatography product family, is a detector that delivers two- and three-dimensional chromatographic information. The detector offers high sampling speeds, a good detection range, high data acquisition
    • Automated Benchtop Cell Sorter
    • Bio-Rad
    • The S3 is a cell-sorting system for core facilities and individual research labs. It is designed to ease bottlenecks by serving as a supplementary instrument for basic cell-sorting work. Equipped with one or two lasers (488 nm and either 561 or 640
    • Automated Microplate Dispenser
    • BioTek Instruments
    • The MultiFlo FX offers up to four independent reagent dispensers and a washer in one platform. Designed to automate microplate-based liquid handling processes, the MultiFlo FX can be used for 6- to 1,536-well plates. It allows a choice of peristalt
    • High-Content Imaging System
    • PerkinElmer
    • Live cell capabilities have been added to the Operetta system including brightfield imaging and environmental chamber options, as well as a transmitted light digital phase-contrast mode that can be used to image and segment live cells without using
    • ELISA Kits
    • Abcam
    • SimpleStep kits are single-wash, colorimetric sandwich ELISAs that are designed to retain the familiar ELISA process and data outputs. Designed for users who may lack specialized training or instrumentation, SimpleStep kits can be used with fewer s
  • Page 1 of 1 (5 items) 1 

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?